Cue Biopharma (CUE) Invested Capital (2017 - 2025)

Cue Biopharma has disclosed Invested Capital across 9 years of filings, most recently posting $26.4 million for Q4 2025.

• Invested Capital for Q4 2025 came in at $26.4 million, up 21.07% year-over-year; the trailing twelve-month figure through Dec 2025 was $26.4 million (up 21.07% YoY), and the FY2025 annual result was $26.4 million, up 21.07% from the prior year.
• Invested Capital came in at $26.4 million for Q4 2025 at Cue Biopharma, up from $14.7 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $73.7 million in Q4 2022 to a low of $10.0 million in Q1 2025.
• The 5-year median for Invested Capital is $49.8 million (2023), against an average of $45.4 million.
• Across the five-year window, Invested Capital jumped 54.01% in 2021 and slumped 69.87% in 2025, its largest moves.
• Cue Biopharma's Invested Capital stood at $65.5 million in 2021, then increased by 12.51% to $73.7 million in 2022, then slumped by 44.24% to $41.1 million in 2023, then tumbled by 46.86% to $21.8 million in 2024, then grew by 21.07% to $26.4 million in 2025.
• The last three Invested Capital figures came in at $26.4 million (Q4 2025), $14.7 million (Q3 2025), and $20.6 million (Q2 2025), per Business Quant data.